Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

89.20 

0.48 0.5%

as of Dec 10 '19

52 Week Range:

70.89 89.24


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Merck & Co., Inc. provides healthcare solutions worldwide. It operates in Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fish. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; horse fertility management products; dog, cat, and horse vaccines; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; Themis Bioscience; I-MAB Biopharma Co., Ltd.; 4D pharma plc; and Promega Corporation. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 8.87
19.00
17.64
18.13
17.52
16.20
15.93
16.39
15.91
14.18
12.51
growth rate 114.2% -7.2% 2.8% -3.4% -7.5% -1.7% 2.9% -2.9% -10.9% -11.8%
Earnings BIT 9,810.00
15,290.00
1,650.00
7,330.00
9,453.00
6,346.00
9,347.00
8,663.00
10,071.00
8,148.00
9,599.00
growth rate 55.9% -89.2% 344.2% 29.0% -32.9% 47.3% -7.3% 16.3% -19.1% 17.8%
Avg.PE 8.35
6.44
131.58
18.66
20.41
34.01
13.97
33.38
32.64
58.53
33.41
growth rate -22.9% 1,943.2% -85.8% 9.4% 66.6% -58.9% 138.9% -2.2% 79.3% -42.9%
ROA 16.34
16.20
0.79
5.93
5.84
4.16
11.69
4.44
3.98
2.61
7.30
growth rate -0.9% -95.1% 650.6% -1.5% -28.8% 181.0% -62.0% -10.4% -34.4% 179.7%
ROE 42.27
33.15
1.52
11.49
11.47
8.57
24.22
9.52
9.25
6.43
20.38
growth rate -21.6% -95.4% 655.9% -0.2% -25.3% 182.6% -60.7% -2.8% -30.5% 217.0%
ROIC 31.92
25.73
1.71
9.17
8.90
6.41
16.87
6.62
6.08
4.23
11.82
growth rate -19.4% -93.4% 436.3% -2.9% -28.0% 163.2% -60.8% -8.2% -30.4% 179.4%
Cur. Ratio 1.35
1.80
1.86
2.04
1.90
2.00
1.77
1.55
1.78
1.33
1.17
growth rate 33.3% 3.3% 9.7% -6.9% 5.3% -11.5% -12.4% 14.8% -25.3% -12.0%
Quick Ratio 0.65
1.02
1.25
1.43
1.30
1.38
1.19
1.04
1.24
0.83
0.72
growth rate 56.9% 22.6% 14.4% -9.1% 6.2% -13.8% -12.6% 19.2% -33.1% -13.3%
Leverage 2.52
1.89
1.95
1.93
2.00
2.12
2.02
2.28
2.38
2.56
3.09
growth rate -25.0% 3.2% -1.0% 3.6% 6.0% -4.7% 12.9% 4.4% 7.6% 20.7%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 2,907.70
6,603.00
7,344.00
11,955.00
7,672.00
7,184.00
6,671.00
6,518.00
7,018.00
6,918.00
7,226.00
growth rate 127.1% 11.2% 62.8% -35.8% -6.4% -7.1% -2.3% 7.7% -1.4% 4.5%
Acct.Payable 14,255.00
1,753.00
2,274.00
2,625.00
2,533.00
2,807.00
3,102.00
3,318.00
growth rate -87.7% 29.7% 15.4% -3.5% 10.8% 10.5% 7.0%
Cur.Assets 19,112.60
28,432.00
29,064.00
33,181.00
34,857.00
35,685.00
32,605.00
29,751.00
30,614.00
24,766.00
25,875.00
growth rate 48.8% 2.2% 14.2% 5.1% 2.4% -8.6% -8.8% 2.9% -19.1% 4.5%
Total Assets 47,195.70
112,314.00
105,781.00
105,128.00
106,132.00
105,645.00
98,167.00
101,677.00
95,377.00
87,872.00
82,637.00
growth rate 138.0% -5.8% -0.6% 1.0% -0.5% -7.1% 3.6% -6.2% -7.9% -6.0%
Cash 4,368.30
9,311.00
10,900.00
13,531.00
13,451.00
15,621.00
7,441.00
8,524.00
6,515.00
6,092.00
7,965.00
growth rate 113.2% 17.1% 24.1% -0.6% 16.1% -52.4% 14.6% -23.6% -6.5% 30.8%
Inventory 2,091.00
8,048.00
5,868.00
6,254.00
6,535.00
6,226.00
5,571.00
4,700.00
4,866.00
5,096.00
5,440.00
growth rate 284.9% -27.1% 6.6% 4.5% -4.7% -10.5% -15.6% 3.5% 4.7% 6.8%
Cur.Liabilities 14,318.70
15,641.00
15,641.00
16,245.00
18,348.00
17,868.00
18,397.00
19,201.00
17,204.00
18,614.00
22,206.00
growth rate 9.2% 0.0% 3.9% 13.0% -2.6% 3.0% 4.4% -10.4% 8.2% 19.3%
Liabilities 28,437.40
53,256.00
51,405.00
50,611.00
53,112.00
55,880.00
49,376.00
56,910.00
55,069.00
53,303.00
55,755.00
growth rate 87.3% -3.5% -1.5% 4.9% 5.2% -11.6% 15.3% -3.2% -3.2% 4.6%
LT Debt 3,943.30
16,095.00
15,482.00
15,525.00
16,254.00
20,539.00
18,714.00
23,852.00
24,303.00
21,405.00
19,887.00
growth rate 308.2% -3.8% 0.3% 4.7% 26.4% -8.9% 27.5% 1.9% -11.9% -7.1%
Equity 18,758.30
59,058.00
54,376.00
54,517.00
53,020.00
49,765.00
48,647.00
44,676.00
40,088.00
34,336.00
26,701.00
growth rate 214.8% -7.9% 0.3% -2.8% -6.1% -2.3% -8.2% -10.3% -14.4% -22.2%
Common Shares 2,143.00
2,273.00
3,120.00
3,094.00
3,076.00
2,996.00
2,928.00
2,841.00
2,787.00
2,748.00
2,679.00
growth rate 6.1% 37.3% -0.8% -0.6% -2.6% -2.3% -3.0% -1.9% -1.4% -2.5%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 1,298.30
0.00
0.00
1,723.00
1,954.00
1,548.00
1,317.00
1,283.00
1,614.00
1,888.00
2,615.00
growth rate -100.0% 13.4% -20.8% -14.9% -2.6% 25.8% 17.0% 38.5%
Cash Dividends 3,400.30
3,479.00
4,853.00
4,691.00
5,236.00
5,277.00
5,170.00
5,117.00
5,124.00
5,167.00
5,172.00
growth rate 2.3% 39.5% -3.3% 11.6% 0.8% -2.0% -1.0% 0.1% 0.8% 0.1%
Cash From OA 6,571.70
3,392.00
10,822.00
12,383.00
10,022.00
11,654.00
7,989.00
12,538.00
10,376.00
6,451.00
10,922.00
growth rate -48.4% 219.0% 14.4% -19.1% 16.3% -31.5% 56.9% -17.2% -37.8% 69.3%
FCF per Share 2.46
0.85
2.93
3.51
2.62
2.82
3.66
1.65
3.33
1.57
3.31
growth rate -65.5% 244.7% 19.8% -25.4% 7.6% 29.8% -54.9% 101.8% -52.9% 110.8%
Sale Purchase of Stock -1,720.00
-2,591.00
-6,516.00
1,560.00
485.00
939.00
-3,515.00
growth rate 0.0% 0.0% 100.0% -68.9% 93.6% -100.0%
FCF 5,273.00
1,931.00
9,144.00
10,660.00
8,068.00
10,106.00
5,543.00
11,138.00
8,762.00
4,559.00
8,307.00
growth rate -63.4% 373.5% 16.6% -24.3% 25.3% -45.2% 100.9% -21.3% -48.0% 82.2%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 23,850.30
27,428.00
45,987.00
48,047.00
47,267.00
44,033.00
42,237.00
39,498.00
39,807.00
40,122.00
42,294.00
growth rate 15.0% 67.7% 4.5% -1.6% -6.8% -4.1% -6.5% 0.8% 0.8% 5.4%
Op.Income 5,053.00
2,387.00
2,370.00
6,882.00
6,299.00
4,517.00
9,347.00
8,663.00
10,071.00
8,148.00
9,599.00
growth rate -52.8% -0.7% 190.4% -8.5% -28.3% 106.9% -7.3% 16.3% -19.1% 17.8%
IBT 9,931.70
15,290.00
1,653.00
7,334.00
8,739.00
5,545.00
17,283.00
5,401.00
4,659.00
6,521.00
8,701.00
growth rate 54.0% -89.2% 343.7% 19.2% -36.6% 211.7% -68.8% -13.7% 40.0% 33.4%
Net Income 7,808.40
12,899.00
861.00
6,882.00
6,168.00
4,404.00
11,920.00
4,442.00
3,920.00
2,394.00
6,220.00
growth rate 65.2% -93.3% 699.3% -10.4% -28.6% 170.7% -62.7% -11.8% -38.9% 159.8%
EPS 3.63
5.65
0.28
2.02
2.00
1.47
4.07
1.56
1.41
0.87
2.32
growth rate 55.7% -95.0% 621.4% -1.0% -26.5% 176.9% -61.7% -9.6% -38.3% 166.7%
Gross Profit 18,267.80
18,409.00
27,591.00
31,176.00
37,799.00
27,079.00
27,051.00
25,075.00
26,305.00
27,482.00
28,806.00
growth rate 0.8% 49.9% 13.0% 21.2% -28.4% -0.1% -7.3% 4.9% 4.5% 4.8%
R&D 4,805.30
5,845.00
11,111.00
8,467.00
8,168.00
7,503.00
6,532.00
6,613.00
6,921.00
9,818.00
9,652.00
growth rate 21.6% 90.1% -23.8% -3.5% -8.1% -12.9% 1.2% 4.7% 41.9% -1.7%

Quarterly Statements

Item Name Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Earnings BIT 2,903.00
2,641.00
3,544.00
3,980.00
4,443.00
growth rate -9.0% 34.2% 12.3% 11.6%
Balance Sheet Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Acct.Receivable 7,374.00
7,226.00
7,796.00
8,208.00
8,714.00
growth rate -2.0% 7.9% 5.3% 6.2%
Acct.Payable 3,091.00
3,318.00
4,159.00
4,456.00
4,468.00
growth rate 7.3% 25.4% 7.1% 0.3%
Cur.Assets 26,836.00
25,875.00
25,351.00
24,298.00
26,142.00
growth rate -3.6% -2.0% -4.2% 7.6%
Total Assets 85,130.00
82,637.00
82,354.00
83,965.00
83,331.00
growth rate -2.9% -0.3% 2.0% -0.8%
Cash 7,826.00
7,965.00
8,076.00
6,659.00
7,869.00
growth rate 1.8% 1.4% -17.6% 18.2%
Inventory 5,416.00
5,440.00
5,712.00
5,847.00
5,855.00
growth rate 0.4% 5.0% 2.4% 0.1%
Cur.Liabilities 18,586.00
22,206.00
18,543.00
20,085.00
20,684.00
growth rate 19.5% -16.5% 8.3% 3.0%
Liabilities 52,474.00
55,755.00
54,684.00
56,228.00
56,406.00
growth rate 6.3% -1.9% 2.8% 0.3%
LT Debt 20,074.00
19,887.00
22,757.00
22,773.00
22,677.00
growth rate -0.9% 14.4% 0.1% -0.4%
Equity 32,422.00
26,701.00
27,539.00
27,635.00
26,838.00
growth rate -17.7% 3.1% 0.4% -2.9%
Common Shares 1,788.00
1,788.00
1,788.00
1,788.00
1,788.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Capital Expenditures 653.00
929.00
595.00
782.00
959.00
growth rate 42.3% -36.0% 31.4% 22.6%
Cash Dividends 1,285.00
1,277.00
1,428.00
1,468.00
1,394.00
growth rate -0.6% 11.8% 2.8% -5.0%
Cash From OA 2,793.00
3,592.00
1,336.00
3,084.00
4,226.00
growth rate 28.6% -62.8% 130.8% 37.0%
Sale Purchase of Stock
growth rate
FCF 2,140.00
2,663.00
741.00
2,302.00
3,267.00
growth rate 24.4% -72.2% 210.7% 41.9%
Income Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Sales 10,794.00
10,998.00
10,816.00
11,760.00
12,397.00
growth rate 1.9% -1.7% 8.7% 5.4%
Op.Income 2,903.00
2,641.00
3,544.00
3,980.00
4,443.00
growth rate -9.0% 34.2% 12.3% 11.6%
IBT 2,665.00
2,604.00
3,067.00
3,259.00
2,347.00
growth rate -2.3% 17.8% 6.3% -28.0%
Net Income 1,950.00
1,827.00
2,915.00
2,670.00
1,901.00
growth rate -6.3% 59.6% -8.4% -28.8%
EPS
growth rate
Gross Profit 7,299.00
7,582.00
7,798.00
8,493.00
9,081.00
growth rate 3.9% 2.9% 8.9% 6.9%
R&D 2,072.00
2,459.00
1,970.00
2,186.00
2,221.00
growth rate 18.7% -19.9% 11.0% 1.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (13.33)

YOY Growth Grade:

F (5.05)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 23.50 24.92 14.91
EPS / Growth 3.6% 3.58 5.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 3.4% 3.4%
Future PE 2.00 15.06 15.06
Future EPS 3.95 4.99 4.99
Value Price
MOS %
1.95
-97.8%
18.57
-79.2%
18.57
-79.2%
MOS Price 0.98 9.29 9.29
IRT 22.16 17.93 17.93

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.